Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4D Molecular Therapeutics ( (FDMT) ) has issued an update.
On September 30, 2025, 4D Molecular Therapeutics appointed Ashoo Gupta as Principal Financial Officer and Principal Accounting Officer, following his role as Vice President, Finance & Controller since June 2024. Additionally, the Board amended the company’s bylaws to update procedures for business meetings and director nominations, reflecting an effort to streamline governance practices.
The most recent analyst rating on (FDMT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
The company’s stock score is primarily impacted by its financial challenges, with persistent negative income and cash flow issues despite a strong cash position on the balance sheet. Positive technical indicators provide some optimism, but the lack of profitability and a negative P/E ratio weigh heavily on the valuation.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing transformative gene therapies. The company specializes in creating targeted treatments for genetic diseases, leveraging advanced molecular technology to address unmet medical needs.
Average Trading Volume: 1,166,681
Technical Sentiment Signal: Hold
Current Market Cap: $407.7M
Find detailed analytics on FDMT stock on TipRanks’ Stock Analysis page.